1. Scrip
  2. >>Business

Remsima Stars In Orion Pharma’s First Half

 
• By John Davis

Sales in Scandinavia of the biosimilar infliximab drove Orion’s specialty business in the first six months of 2016.

Orion
The Orion Constellation

The biosimilar Remsima (infliximab), a generic version of Johnson & Johnson/Merck & Co. Inc.’s Remicade, became the fifth best-selling product for Finland’s Orion Pharma during the first half of 2016, achieving sales of €22m (+161%) and accounting for 4% of Orion’s sales revenues of €535m in the half.

“Orion continued to enjoy winning some tenders here in Scandinavia, where we sell the product,” commented company CEO Timo Lappalainen...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.